Audrey Nadine Jajosky

Dr. Audrey Nadine Jajosky

University of Rochester Medical Center, Rochester, Indiana, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AJAudrey Nadine Jajosky
Audrey Nadine Jajosky
NSNavid Sadri
Navid Sadri
HMHoward J. Meyerson
Howard J. Meyerson
KOKwadwo A. Oduro
Kwadwo A. Oduro
AKAshwin Kelkar
Ashwin Kelkar
RBRose C. Beck
Rose C. Beck

19 November 2020 in American Journal of Clinical Pathology
Verified
Journal Article
Closed access
CGCatherine K Gestrich
Catherine K Gestrich
AJAudrey Nadine Jajosky
Audrey Nadine Jajosky
RERobin Elliott
Robin Elliott
DSDuncan Stearns
Duncan Stearns
NSNavid Sadri
Navid Sadri
MCMarta E Couce
Marta E Couce
Objectives: Although glioblastoma (GBM) is rare in the pediatric population, it is the most common cause of death among children with central nervous system neoplasms. Recent molecular profiling of these neoplasms has demonstrated distinct differences in comparison to their adult counterparts. Moreover, many pediatric GBMs occur within the context of cancer predisposition syndromes, such as constitutional mismatch repair deficiency syndrome (CMMRD). Children with CMMRD who develop GBM exhibit a high tumor mutational burden and may benefit from treatment with immune checkpoint inhibitors. Methods: We performed next-generation sequencing and immunohistochemistry for mismatch repair proteins in our cohort of pediatric and adult GBMs to further characterize the molecular profiles of these groups. Results: We examined a total of 11 pediatric and 11 adult GBMs. Pediatric patients had a higher number of alterations compared to their adult counterparts. They also had a higher frequency of alterations in the mismatch repair genes, which can be detected by immunohistochemistry (IHC). We also identified one pediatric patient with CMMRD syndrome. Conclusions: Our study highlighted the distinct molecular differences between pediatric and adult GBM. We also demonstrated that pediatric patients have a higher frequency of alterations in the mismatch repair genes, which may render them susceptible to treatment with immune checkpoint inhibitors. These alterations can be detected using routine IHC and should be performed on all pediatric GBM.

11 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
TLThomas D. Lee
Thomas D. Lee
DADara L. Aisner
Dara L. Aisner
MDMarjorie P. David
Marjorie P. David
CECeleste Eno
Celeste Eno
JGJeffrey Gagan
Jeffrey Gagan
AKAnnette S. Kim
Annette S. Kim
While molecular testing of hematologic malignancies is now standard of care, there is variability in practice and testing capabilities between different academic laboratories, with common questions arising on how to best meet clinical expectations. A survey was sent to hematopathology subgroup members of the Genomics Organization for Academic Laboratories consortium to assess current and future practice and potentially establish a reference for peer institutions. Responses were received from 18 academic tertiary-care laboratories regarding next-generation sequencing (NGS) panel design, sequencing protocols and metrics, assay characteristics, laboratory operations, case reimbursement, and development plans. Differences in NGS panel size, use, and gene content were reported. Gene content for myeloid processes was reported to be generally excellent, while genes for lymphoid processes were less well covered. The turnaround time (TAT) for acute cases, including acute myeloid leukemia, was reported to range from 2 to 7 calendar days to 15 to 21 calendar days, with different approaches to achieving rapid TAT described. To help guide NGS panel design and standardize gene content, consensus gene lists based on current and future NGS panels in development were generated. Most survey respondents expected molecular testing at academic laboratories to continue to be viable in the future, with rapid TAT for acute cases likely to remain an important factor. Molecular testing reimbursement was reported to be a major concern. The results of this survey and subsequent discussions improve the shared understanding of differences in testing practices for hematologic malignancies between institutions and will help provide a more consistent level of patient care.

1 January 2018 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
RJRyan Philip Jajosky
Ryan Philip Jajosky
AJAudrey Nadine Jajosky
Audrey Nadine Jajosky
PJPhilip Jajosky
Philip Jajosky
Cite this article as: Jajosky RP, Jajosky AN, Jajosky PG. Can Therapeutically-Rational Exchange (T-REX) of Thalassemic Red Blood Cells Improve the Clinical Course of Plasmodium falciparum Malaria? Eurasian J Med 2018; 50(3): 215-216.


18 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
GGGiby George
Giby George
MKMalgorzata Kajstura
Malgorzata Kajstura
AJAudrey Nadine Jajosky
Audrey Nadine Jajosky
HFHong Fang
Hong Fang
FJFatima Zahra Jelloul
Fatima Zahra Jelloul
Siba El HusseinSiba El Hussein
Siba El Hussein
Acute myeloid leukemia (AML) with RUNX1::RUNX1T1 fusion is well known to often demonstrate aberrant upregulation of CD19 expression. We studied the clinicopathologic and genetic features of 16 cases of AML with various RUNX1 lesions, including mutations, copy number gains, and translocations other than fusions with RUNX1T1. Most of these cases were classified as AML-myelodysplasia-related or AML-post-cytotoxic therapy based on the cytogenetic and molecular work-up. These neoplasms showed partial expression of one or more B-cell antigens by flow cytometry and/or immunohistochemistry, fulfilling the criteria for mixed-phenotype acute leukemia (MPAL)-B/myeloid (i.e., ≥20% blasts expressing B and myeloid lineage antigens) in most cases. These findings suggest that AML cases with RUNX1 lesions including mutations, copy number gains, and translocations other than RUNX1T1 fusion, also commonly express B-cell markers, imparting a “mixed-lineage-like” immunophenotype in cases of AML that otherwise fulfill the criteria for other defined subtypes. We present these cases as to caution regarding this potential diagnostic pitfall and favor a diagnosis of AML with RUNX1 lesion(s) in the setting of a case of AML with myeloid/B-cell antigen expression, a history of myelodysplasia or cytotoxic therapy, the demonstration of pDC differentiation by flow cytometry (generally associated with the presence of a RUNX1 mutation), and the presence of a RUNX1 lesion (mutation, copy number gain, and/or translocation exclusive of a rearrangement with RUNX1T1).